DNDi has released the 2021 Annual Report.
The 2021 Annual Report describes recent developments towards the realization of the core commitments of DNDi's 2021-2028 Strategic Plan. Progress has been made in 50 research and development (R & D) projects in 2021, especially in the area of FDA approval of fexinidazole, a treatment for African sleeping sickness, and clinical trials of five new compounds for squirrel mania. There has been great progress.
A detailed summary and PDF of the report can be found at this link .